<DOC>
	<DOCNO>NCT02748018</DOCNO>
	<brief_summary>The purpose study demonstrate safety effectiveness Hybrid Closed Loop system ( HCL ) adult pediatric patient type 1 diabetes home setting . A diverse population patient type 1 diabetes study . The study population large range duration diabetes glycemic control , measure glycosylated hemoglobin ( A1C ) . They enrol study regardless prior diabetes regimen , include use Multiple Daily Injections ( MDI ) , Continuous Subcutaneous Insulin Infusion ( CSII ) Sensor-Augmented Pump therapy ( SAP )</brief_summary>
	<brief_title>Multi-center Trial Adult Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System Home</brief_title>
	<detailed_description>This 6 month , multi-center , randomize , parallel , adaptive study type 1 diabetes 6 month continuation period . The study three period : 1 . Run-in Period : The run-in period 60 day time blind CGM sensor wear two week . 2 . Study Period : There 6 month randomize study period two arm : The HCL system Control . 3 . Continuation Period : There 6 month continuation period time subject use HCL system Auto Mode . Up 1500 subject enrol order 1000 subject complete study . Up 70 investigational Centers US Canada , well Medtronic EMEA region , comprise Europe , Middle East Africa , enrol .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Subject age 775 year time screen 2 . Subjects 721 year determine investigator appropriate , requisite support ( family , caregiver social network ) successfully participate study 3 . Subject must minimum daily insulin requirement ( Total Daily Dose ) great 8 units/day 4 . Subjects determine investigator psychologically sound order successfully participate study 5 . Subject diagnose type 1 diabetes least three month Note : Determination classification diabetes base American Diabetes Association Clinical Practice Guidelines account several patient characteristic : age onset , patient 's weight BMI , history diabetic ketoacidosis , history therapy management , medical record available . 6 . Subject must one follow management therapy : Multiple daily injection define use rapid analogue meal long act analogue ( i.e . detemir glargine ) , without CGM Insulin pump therapy without CGM 7 . Subject willing perform ≥ 4 finger stick blood glucose measurement daily 8 . Subject willing perform require sensor calibration 9 . Subject willing wear system continuously throughout study least 80 % time . 10 . Subject willing upload data least weekly study pump , must Internet access computer system meet requirement upload study pump 11 . Subject must able speak literate English 12 . If subject celiac disease , adequately treat determined investigator 13 . Subject diagnosis myocardial infarction , unstable angina , coronary artery bypass surgery , coronary artery stenting , transient ischemic attack , cerebrovascular accident , angina , congestive heart failure , ventricular rhythm disturbance thromboembolic disease , within 1 year screening , include study consent subject 's cardiologist 14 . Subject willing take one follow insulin financially afford use either 2 insulin preparation throughout course study ( i.e . copayments insulin insurance able pay full amount ) 1 . Humalog® ( insulin lispro injection ) 2 . NovoLog® ( insulin aspart ) 1 . Subject MDI concurrent CGM therapy least 3 month prior Screening 2 . Subject participate Closed Loop study past . 3 . Subject unable tolerate tape adhesive area sensor placement 4 . Subject unresolved adverse skin condition area sensor placement ( e.g. , psoriasis , rash , Staphylococcus infection ) area infusion set placement 5 . Women childbearing potential positive pregnancy test screening plan become pregnant course study 6 . Subject treat hyperthyroidism time screen 7 . Subject abnormality ( upper reference range , processed Central Lab ) creatinine time screen visit 8 . Subject abnormality ( reference range , processed Central Lab ) thyroidstimulating hormone ( TSH ) time screen visit 9 . Subject take oral , injectable , IV steroid within 8 week time screen visit , plan take oral , injectable , IV steroids course study . ( Subjects may rescreened 1 month fail exclusion criterion ) 10 . Subject actively participate investigational study ( drug device ) wherein he/she receive treatment investigational study drug investigational study device last 2 week 11 . Subject hospitalize visited emergency room 6 month prior screen result primary diagnosis uncontrolled diabetes ( i.e . diabetic ketoacidosis [ DKA ] ) except related new diagnosis . 12 . Subject currently abuse illicit drug marijuana 13 . Subject currently abuse prescription drug 14 . Subject currently abuse alcohol 15 . Subject use pramlintide ( Symlin ) SGLT2 inhibitor , GLP agonists , biguanides , DPP4 inhibitor sulfonylureas time screen 16 . Subject history visual impairment would allow subject participate study perform study procedure safely , determine investigator 17 . Subject elective surgery plan require general anesthesia course study 18 . Subject sickle cell disease , hemoglobinopathy ; receive red blood cell transfusion erythropoietin within 3 month prior time screen 19 . Subject plan receive red blood cell transfusion erythropoietin course study participation 20 . Subject diagnose current eating disorder anorexia bulimia 21 . Subject diagnose chronic kidney disease result chronic anemia 22 . Subjects currently treat cancer plan treat cancer .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>